Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Mar 15 2019 | Register for HFSA 23rd Annual Scientific Meeting Practice News Annual Scientific Meeting Read More Mar 14 2019 | FDA Approves new Indication for Valve Repair Device to Treat Certain Heart Failure Patients with Mitral Regurgitation Practice News Read More Mar 7 2019 | Call for Nominations for Volunteer Opportunities – 2019 Practice News Read More Mar 5 2019 | MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM Practice News Industry Read More Feb 26 2019 | BRILINTA’s Phase III THEMIS Trial met Primary Endopoint in Patients with Established Coronary Artery Disease and Type-2 Diabetes Practice News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 116 Page 117 Page 118 Page 119 Current page 120 Page 121 Page 122 Page 123 Page 124 … Next page Next › Last page Last »
Mar 15 2019 | Register for HFSA 23rd Annual Scientific Meeting Practice News Annual Scientific Meeting Read More
Mar 14 2019 | FDA Approves new Indication for Valve Repair Device to Treat Certain Heart Failure Patients with Mitral Regurgitation Practice News Read More
Mar 5 2019 | MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM Practice News Industry Read More
Feb 26 2019 | BRILINTA’s Phase III THEMIS Trial met Primary Endopoint in Patients with Established Coronary Artery Disease and Type-2 Diabetes Practice News Industry Read More
